Literature DB >> 23108433

Role of late sodium channel current block in the management of atrial fibrillation.

Alexander Burashnikov1, Charles Antzelevitch.   

Abstract

The anti-arrhythmic efficacy of the late sodium channel current (late I(Na)) inhibition has been convincingly demonstrated in the ventricles, particularly under conditions of prolonged ventricular repolarization. The value of late I(Na) block in the setting of atrial fibrillation (AF) remains poorly investigated. All sodium channel blockers inhibit both peak and late I(Na) and are generally more potent in inhibiting late vs. early I(Na). Selective late I(Na) block does not prolong the effective refractory period (ERP), a feature common to practically all anti-AF agents. Although the late I(Na) blocker ranolazine has been shown to be effective in suppression of AF, it is noteworthy that at concentrations at which it blocks late I(Na) in the ventricles, it also potently blocks peak I(Na) in the atria, thus causing rate-dependent prolongation of ERP due to development of post-repolarization refractoriness. Late I(Na) inhibition in atria is thought to suppress intracellular calcium (Ca(i))-mediated triggered activity, secondary to a reduction in intracellular sodium (Na(i)). However, agents that block late I(Na) (ranolazine, amiodarone, vernakalant, etc) are also potent atrial-selective peak I(Na) blockers, so that the reduction of Na(i) loading in atrial cells by these agents can be in large part due to the block of peak I(Na). The impact of late I(Na) inhibition is reduced by the abbreviation of the action potential that occurs in AF patients secondary to electrical remodeling. It stands to reason that selective late I(Na) block may contribute more to inhibition of Ca(i)-mediated triggered activity responsible for initiation of AF in clinical pathologies associated with a prolonged atrial APD (such as long QT syndrome). Additional studies are clearly needed to test this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23108433      PMCID: PMC3557765          DOI: 10.1007/s10557-012-6421-1

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  81 in total

1.  Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism.

Authors:  Colleen E Clancy; Yoram Rudy
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

2.  Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model.

Authors:  Tuomo Nieminen; Danilo Y Nanbu; Ibere P Datti; Gabriel R Vaz; Caio A M Tavares; José R M Pegler; Bruce D Nearing; Luiz Belardinelli; Richard L Verrier
Journal:  Heart Rhythm       Date:  2010-11-19       Impact factor: 6.343

3.  Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine.

Authors:  Norishige Morita; Jong Hwan Lee; Yuanfang Xie; Ali Sovari; Zhilin Qu; James N Weiss; Hrayr S Karagueuzian
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

4.  Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation.

Authors:  Evgeny P Anyukhovsky; Eugene A Sosunov; Parag Chandra; Tove S Rosen; Penelope A Boyden; Peter Danilo; Michael R Rosen
Journal:  Cardiovasc Res       Date:  2004-11-10       Impact factor: 10.787

5.  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Authors:  Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2010-10-05       Impact factor: 24.094

Review 6.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

7.  Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Authors:  Kapil Kumar; Bruce D Nearing; Marcelo Carvas; Bruno C G Nascimento; Mariana Acar; Luiz Belardinelli; Richard L Verrier
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

8.  Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block.

Authors:  Alexander Burashnikov; Sandeep Mannava; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-06       Impact factor: 4.733

9.  Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart.

Authors:  Kapil Kumar; Bruce D Nearing; Carlo R Bartoli; Kevin F Kwaku; Luiz Belardinelli; Richard L Verrier
Journal:  J Cardiovasc Electrophysiol       Date:  2008-05-09

10.  Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

View more
  17 in total

Review 1.  Antiarrhythmic drugs 2013: state of the art.

Authors:  Kapil Kumar; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

2.  Multi-channel blockers for treatment of atrial fibrillation: an effective strategy?

Authors:  David R Van Wagoner
Journal:  Cardiovasc Res       Date:  2013-03-01       Impact factor: 10.787

Review 3.  Late sodium current associated cardiac electrophysiological and mechanical dysfunction.

Authors:  Shandong Yu; Gang Li; Christopher L-H Huang; Ming Lei; Lin Wu
Journal:  Pflugers Arch       Date:  2017-11-10       Impact factor: 3.657

4.  Classification and reporting of severity experienced by animals used in scientific procedures: FELASA/ECLAM/ESLAV Working Group report.

Authors:  David Smith; David Anderson; Anne-Dominique Degryse; Carla Bol; Ana Criado; Alessia Ferrara; Nuno Henrique Franco; Istvan Gyertyan; Jose M Orellana; Grete Ostergaard; Orsolya Varga; Hanna-Marja Voipio
Journal:  Lab Anim       Date:  2018-02       Impact factor: 2.471

5.  Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.

Authors:  Drayton A Hammond; Carmen Smotherman; Christopher A Jankowski; Stephen Tan; Omeni Osian; Dale Kraemer; Marci DeLosSantos
Journal:  Clin Res Cardiol       Date:  2014-11-22       Impact factor: 5.460

6.  Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes.

Authors:  Tian Zou; Qingxing Chen; Chaofeng Chen; Guijian Liu; Yunlong Ling; Yang Pang; Ye Xu; Kuan Cheng; Wenqing Zhu; Ru-Xing Wang; Ling-Ling Qian; Junbo Ge
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

7.  Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.

Authors:  Istvan Baczko; David Liknes; Wei Yang; Kevin C Hamming; Gavin Searle; Kristian Jaeger; Zoltan Husti; Viktor Juhasz; Gergely Klausz; Robert Pap; Laszlo Saghy; Andras Varro; Vernon Dolinsky; Shaohua Wang; Vivek Rauniyar; Dennis Hall; Jason Rb Dyck; Peter E Light
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 8.  Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.

Authors:  Francesco De Sensi; Tom De Potter; Alberto Cresti; Silva Severi; Günter Breithardt
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

Review 9.  The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?

Authors:  A John Camm
Journal:  Curr Cardiol Rev       Date:  2014-11

10.  Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels.

Authors:  Mohammad-Reza Ghovanloo; Mena Abdelsayed; Peter C Ruben
Journal:  Front Pharmacol       Date:  2016-03-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.